LobbyingAmarin Pharma lobbying by quarter
Amarin Pharma's latest lobbying report covers Q2 2025, at under $5,000. Its first report covers Q2 2024; the issues it reports most are Health Issues.
Amarin Pharma
- Latest quarter
- No record
- Q3 2026 · 0 reports
- Last 12 months
- $0
- Last 4 quarters
- vs last quarter
- No record
- Q3 2026 against the quarter before
- First report
- Q2 2024
- The first quarter a report named it
Lobbying by quarter
| Quarter | Amount | Reports |
|---|---|---|
| Q2 2024 | $10K | 1 |
| Q3 2024 | $10K | 1 |
| Q4 2024 | $0 | 1 |
| Q1 2025 | $0 | 1 |
| Q2 2025 | $0 | 1 |
| Q3 2025 | $0 | 0 |
| Q4 2025 | $0 | 0 |
| Q1 2026 | $0 | 0 |
| Q2 2026 | $0 | 0 |
| Q3 2026 | $0 | 0 |
By issue
- Health issues$20K · 2 reports
An issue's amount splits each report's amount equally over the issues the report lists.
Who was lobbied
- Centers For Medicare and Medicaid Services (CMS)2 reports
- HOUSE OF REPRESENTATIVES2 reports
- SENATE2 reports
Firms it paid
| Firm | ||
|---|---|---|
| King & Spalding | $20K | 5 quarters |
Former officials lobbying for it
| Former position | ||
|---|---|---|
| SCOTT DZIENGELSKI | Rep. Murphy (PA-18): Leg. Dir. (2015-2017), Sr. Leg. Asst. (2013-2015), Leg. Asst. (2012-2013), Leg. Corr. (2011-2012), Staff Asst. (2010-2011); Energy and Commerce Committee: Staff (2015-2017) | Q3 2024 |
Lobbying reports
| Filed by | ||
|---|---|---|
| 25/07/21for Q2 2025 | King & Spalding | Under $5,000 |
| 25/04/17for Q1 2025 | King & Spalding | Under $5,000 |
| 25/01/14for Q4 2024 | King & Spalding | Under $5,000 |
| 24/10/18for Q3 2024 | King & Spalding | $10K |
| 24/07/22for Q2 2024 | King & Spalding | $10K |
| 24/05/07for Q2 2024 | King & Spalding | Under $5,000 |